Intuitive Surgical, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +15

If Intuitive Surgical Stock Looks Expensive, You Need To Read This

Financial outlook AI-generated analysis

πŸ“ˆ Intuitive Surgical trades at a forward multiple of roughly 40x adjusted earnings, implying significant growth expectations for future profitability.

πŸ“Š Analysts forecast net income to reach $3.99 billion in fiscal 2026 and $4.55 billion in fiscal 2027.

πŸ“‰ Revenue growth is expected to slow to 12.1% in fiscal 2027 compared to the 20.5% reported over the last twelve months.

πŸ” Management expects worldwide da Vinci procedures to grow between 14% and 15% in fiscal 2026.

πŸ’° Net margins are forecasted to expand from 31.5% in fiscal 2025 to 34.1% in fiscal 2027.

πŸ“‰ Instrument pricing actions, including a price reduction in China, are expected to lower revenue per procedure by 3% to 5%.

⚠️ Management anticipates higher input costs in areas such as freight and semiconductor memory for the upcoming fiscal year.

πŸ—“οΈ Operating expense guidance for fiscal 2027 is pending and will be released in January 2027.

πŸ›‘οΈ The stock is currently priced based on future profit levels that Intuitive Surgical has not yet realized.

βš–οΈ A shortfall in margin expansion due to pricing cuts or cost increases would make the current valuation a riskier bet.

Bullish Signals
  • Analyst consensus forecasts project net income growth to $3.99 billion in fiscal 2026 and $4.55 billion in fiscal 2027.
  • Management expects worldwide da Vinci procedures to grow by 14% to 15% in fiscal 2026.
  • The consensus forecast assumes a net margin expansion from 31.5% in fiscal 2025 to 34.1% in fiscal 2027.
Risk Factors
  • Management indicated that pricing actions and a price reduction in China will lower da Vinci instrument and accessory revenue per procedure by about 3% to 5% once fully implemented.
  • The company expects higher input costs in areas like freight and semiconductor memory, which could compress profit margins.
  • Operating expense guidance for fiscal 2027 is not yet available, creating uncertainty around the company's cost management strategy.
  • If consensus forecasts do not fully account for pricing cuts and cost increases, both revenue and margin could come in below expectations.
Full Analysis
Intuitive Surgical (ISRG) currently trades at a forward multiple of approximately 40x adjusted earnings over the last twelve months, reflecting investor expectations for significant future growth. Analyst consensus forecasts project net income reaching $3.99 billion in fiscal 2026 and rising to $4.55 billion by fiscal 2027. Under these projections, the company's current market valuation would correspond to a multiple of roughly 39.5x for fiscal 2026 earnings and drop to 34.7x for fiscal 2027, suggesting the stock is priced based on future profitability rather than just past performance. Revenue growth is expected to moderate from the double-digit pace seen recently to approximately 12.1% in fiscal 2027, while management anticipates worldwide da Vinci procedures will increase by 14% to 15% in fiscal 2026. The consensus forecast also assumes a tightening of net margins, projecting a rise from 31.5% in fiscal 2025 to 34.1% in fiscal 2027. This margin expansion is driven by the expectation that the company will retain a higher percentage of sales as profit compared to the roughly 34% retention rate observed over the last twelve months. However, potential headwinds could cause Intuitive Surgical to miss these optimistic forecasts, primarily through pricing pressures and increased operational costs. Management indicated on its Q3 2026 call that price reductions in China and the rollout of longer-life instruments will lower revenue per procedure by 3% to 5%. Additionally, the company faces potential higher input costs related to freight and semiconductor memory, while operating expense guidance for fiscal 2027 is not yet available and will be released in January 2027. If Intuitive Surgical fails to deliver on these margin expansion targets due to the cited pricing cuts or cost increases, the stock could face downside risk as it remains priced for profit levels the company has not yet achieved. Investors are advised to monitor management's upcoming operating expense guidance in January 2027 to assess whether the consensus margin assumptions remain realistic given the anticipated headwinds in instrument pricing and input costs.